

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 01011)

UPDATE ON TRADING HALT AND INSIDE INFORMATION

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcement of the Company dated 26 June 2019 in relation to the halt of trading (the “**Trading Halt**”) in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on 26 June 2019 pending the release of an announcement pursuant to The Codes on Takeovers and Mergers and Shares Buy-backs and containing the inside information of the Company.

The board of directors of the Company (the “**Board**”) wishes to inform the Company’s shareholders and potential investors of the current status of the Company and to provide update on the Trading Halt. As of the date of this announcement, the Company has submitted a draft announcement (the “**Draft Announcement**”) to the Securities and Futures Commission (the “**SFC**”) on 26 June 2019 for its review and vetting. As at the date of this announcement, the Draft Announcement is being reviewed by the SFC and is pending the SFC’s clearance for publication.

The Company has received the first round of comments from the SFC on the Draft Announcement (the “**First Comments**”) and as at the date of this announcement, the Company is working to address the First Comments. The Draft Announcement will be published by the Company upon receiving the SFC’s clearance for publication.

The Board would prepare and/or publish (as the case may be) the Draft Announcement in order to resume trading in the shares of the Company as soon as practicable. Trading of the shares of the Company will remain suspended pending the publication of the Draft Announcement.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 3 July 2019

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu, Mr. Wu Weizhong and Mr. Wang Fei; the non-executive Directors are Dr. Qian Wei and Ms. Lou Jianying; and the independent non-executive Directors are Mr. Patrick Sun, Mr. Tze Shan Hailson Yu and Dr. Hong Yan.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.